The Link Between Glucosamine Joint Supplements And Dementia Risk, Explained

Tens of millions of adults are turning to over-the-counter (OTC) dietary supplements to manage joint stiffness, osteoarthritis-related discomfort, and day-to-day mobility issues. Glucosamine, an amino sugar supplement, is one of the most popular wellness supplements sold in the U.S., with more than 40 million people taking it daily for cartilage support and relief from knee pain, reports Science Alert.

Consumers assume that “natural” dietary products sold without a prescription are safe. Still, new biomedical research shows that these products can sometimes have very different effects depending on an individual’s brain health. A surprising and unsettling link was discovered by biochemists and neurobiologists at the University of Florida in late September 2026 and published in the journal Nature Metabolism: People on regular glucosamine supplements were 25% more likely to develop full clinical dementia from mild cognitive impairment.

Can glucosamine affect dementia?

Yes, the newest clinical and lab data indicate that glucosamine can markedly affect the course of neurodegenerative disease, and that it does so, may be dependent on an individual’s starting cognitive and neurometabolic condition.

Researchers studied the electronic health record data of more than 65,000 patients and analyzed post-mortem human brain tissue, and controlled animal models, to find that glucosamine crosses the blood-brain barrier and can go on to feed into a hyperactive “sugar tagging” system, which coats brain proteins with extra glycans, and which accelerates neurodegenerative damage. To safeguard cognitive longevity, it’s essential to understand the brain’s metabolic processes, identify those who should be cautious, and explore alternative treatments for joint health that do not involve exercise.

Previous population-based observational studies have also reported that regular use of glucosamine in healthy adults without pre-existing memory decline was associated with reduced systemic inflammation and, occasionally, a decrease in dementia risk. But the 2026 University of Florida study assessed the supplement’s effects in a metabolically impaired brain.

When the researchers analyzed the health records of 24,000 people diagnosed with dementia and 41,000 with mild cognitive impairment (MCI), they found that among individuals with MCI, those who took glucosamine were 25% more likely to develop full-blown dementia. Worse, even in patients who had already been diagnosed with Alzheimer’s disease or other forms of dementia, those taking glucosamine regularly had a 25% higher risk of death within five years.

The science behind glucosamine and brain metabolism

To learn more about the effect an OTC joint supplement might have on the central nervous system, researchers turn to cellular-level brain processing of sugars.

Glucosamine is an amino sugar that readily crosses the protective blood-brain barrier. In cells, it is used as a key building block to make complex branched sugar chains called glycans. Under healthy physiological conditions, cells add these sugar structures to newly synthesized proteins through a precise biochemical process called glycosylation. These sugar labels are like molecular shipping labels and structural guides that help cellular proteins assume their proper shape, move to certain cell compartments, and facilitate biological communication.

But in the case of the Alzheimer’s brain, this regulatory machinery goes awry. The University of Florida research team analyzed the brain tissue of deceased Alzheimer’s patients and noted an incredible global increase of abnormal glycan structures when compared to age-matched controls. These sugary coatings were denser in the patient’s cerebral gray matter, the more advanced the Alzheimer’s disease. Independent biochemists in a scientific review published in Nature recognized this phenomenon, known as “protein hyperglycosylation,” as a novel pathological hallmark of Alzheimer’s pathology.

Tunde Rasheed, B.Sc. Researcher in Chemical and Polymer Medical Engineering shares with Blavity, “If that person’s brain metabolism has already been altered due to neurodegeneration, what many researchers now refer to as a localized metabolic failure, or ‘type 3 diabetes,’ the introduction of the external glucosamine provides fuel to an overactive enzymatic fire. The extra amino sugar does not help repair cells; instead, it provides amino sugar to continually hyper-tag proteins in the brain, leading to their misfolding, aggregation, and activation of neurotoxic inflammatory cascades.”

When the glucosamines were fed directly to genetically modified mice models of Alzheimer’s, the memory impairments of the animals were exacerbated, but genetically blocking the enzymes that synthesize these sugars noticeably reversed cognitive symptoms. But remarkably, the same glucosamine was supplied to fully healthy control mice, and no cognitive decline was observed, indicating that the neurotoxic effects of this supplement depend on the presence of a pre-existing neurometabolic vulnerability.

Why safety is a concern

The findings of a possible association between glucosamine and faster cognitive decline highlight important public health issues surrounding the regulation, promotion and unregulated use of dietary supplements sold as over-the-counter medications.

In the United States, dietary supplements are regulated by the Dietary Supplement Health and Education Act (DSHEA) of 1994, which does not require the same rigorous multi-phase RCTs that are conducted before prescription pharmaceuticals are placed on pharmacy shelves to determine dosage range, efficacy and contraindications. In this federal system, the manufacturer does not have to establish safety and effectiveness to the Food and Drug Administration (FDA) before marketing the product to consumers.

As a result, millions of older adults who are the very same ones most vulnerable to age-related cognitive decline and early Alzheimer’s changes routinely buy and take high-dose glucosamine on a day-to-day basis, based on the unverified premise that natural wellness aids have no neurologic downside. Since preclinical stages of Alzheimer’s disease unfold quietly within the brain over 15 to 20 years before clinical diagnosis, millions of older consumers may be unknowingly putting faulty neural circuits under stress with the compounds that promote degeneration of these cells.

Risks and side effects

Glucosamine has been considered a safe supplement, but clinical studies have established that it has systemic physiological side effects and serious and significant central nervous system risks.

The Mayo Clinic has listed the known side effects and clinical risks as:

Systemic and gastrointestinal complications

Oral glucosamine is often associated with systemic side effects such as ongoing nausea, heartburn, abdominal cramping, diarrhea and constipation. Most commercial glucosamine supplements are chemically manufactured from the exoskeletons of shellfish such as shrimp, crabs and lobsters, meaning people with severe crustacean allergies may be at risk of an acute hypersensitivity reaction or anaphylaxis if they don’t take specially formulated vegetarian supplements, which are made from fermented corn.

Metabolic dysregulation and drug interactions

Glucosamine may disrupt the normal metabolism of carbohydrates. Large amounts have been proven to cause peripheral insulin resistance and increase fasting blood sugar levels, which can be problematic for people with prediabetes or type 2 diabetes.

In addition, glucosamine has an alarming pharmacological interaction with the anticoagulant drug, warfarin; when people take both at the same time, it can increase the international normalized ratio (INR), which can lead to spontaneous bleeding and serious internal bleeding.

Neurological and cognitive risks

The greatest threat pointed out by the new Nature Metabolism data is the speeding up of neurodegenerative disease. Excess glucosamine enters the brain and promotes abnormal protein hyperglycosylation in people with mild cognitive impairment or those who are not diagnosed with cerebral amyloid deposition. This leads to neuronal synaptic loss, further exacerbation of neuroinflammation, and accelerates the progression from minor memory problems to severe clinical dementia.

Who should avoid glucosamine?

Based on newly discovered metabolic vulnerabilities, guidelines recommend that certain patient populations either avoid glucosamine or discontinue it after medical advice.

The following groups of people should not take glucosamine supplements based on clinical parameters:

• Patients with mild cognitive impairment (MCI), subjective cognitive decline or a known dementia (such as Alzheimer’s, vascular, or Lewy body) should steer clear of glucosamine, as it has been shown to accelerate disease progression and increase complications and death.
• Older individuals with a strong family history of Alzheimer’s disease or who have the genetic risk factor apolipoprotein E epsilon 4 (APOE-e4) should be very careful because their intrinsic brain metabolic activity might be particularly susceptible to sugar-tagging dysfunction.
• High doses of glucosamine should be avoided in patients with type 2 diabetes or severe metabolic syndrome to avoid undesirable increases in blood glucose and peripheral insulin resistance.
• People who are on prescription blood thinners, especially warfarin, should not use glucosamine because of the possible life-threatening drug interactions.
• People with severe shellfish allergies, mediated by immunoglobulin E (IgE), should not take conventional glucosamine products that are derived from shellfish.

How does your body warn you that dementia is starting?

Identifying early biological and behavioral signs of cognitive decline can lead families to get the medical assessment they need as soon as possible, to review all their daily medications, and to discontinue potentially harmful supplements before the brain is seriously harmed.

The Alzheimer’s Association has put together clinical diagnostic criteria, and the early warning signs that dementia may be developing include:

The most common initial symptom is memory loss that interferes with daily life, such as forgetting recently learned information, asking the same questions over and over, and needing to rely more and more on memory aids or family members for tasks one used to do on one’s own. Some problems in planning and problem-solving may also occur, such as uncharacteristic trouble making a familiar family recipe, keeping track of monthly utility costs, or creating a familiar budget.

When there are problems with routine, everyday activities, people have trouble driving to their local grocery store, operating household appliances, or remembering the rules of a favorite card game. Confusion with time or place occurs when people forget dates, seasons, or the passage of time, or find themselves in a place they know but don’t remember how they got there. These difficulties with visual images and spatial relationships can manifest as trouble judging distance whilst driving, difficulty with contrast, or misinterpreting reflections in mirrors.

When an individual has new word problems in speaking or writing, they stall in the middle of a sentence with no plan for the next word, repeat themselves, or have difficulty selecting words to name everyday objects. Often loses things and cannot retrace steps; often leaves things in strange places (like keys in the freezer) and thinks others may have stolen them.

Poor or diminished judgement may lead to poor decision-making in personal financial matters, increased susceptibility to telemarketing scams, or reduced attention to personal grooming and physical hygiene. People often leave work or other social events early to escape the social environment and conceal cognitive deficits from friends and colleagues. Mood and personality changes include becoming unusually confused, suspicious, depressed, fearful, or easily agitated outside the familiar daily routine.

Best practices for joint health

Older persons and athletes who want to alleviate joint stiffness don’t have to resort to compounds that risk disrupting brain metabolism; evidence-based lifestyle changes and safer natural options can help alleviate joint stiffness without compromising brain metabolism.

According to clinical practice guidelines from the American College of Rheumatology (ACR), safe, proven strategies for preserving joint function include:

Low-impact physical exercise and mobility training

Moderate-intensity, low-impact exercises such as swimming, water aerobics, stationary biking, and tai chi are the most effective treatments for knee and hip osteoarthritis. Movement helps joints produce natural synovial fluid, which lubricates cartilage and nourishes joints without excessive jarring. At the same time, it provides mechanical compressive stress redistribution over the knee joints by strengthening the quadriceps, hamstrings, and gluteus muscles.

Anti-inflammatory nutrition and safe natural compounds

Eating a Mediterranean-style diet that includes wild-caught fatty fish, such as salmon, sardines, and walnuts instead of extra virgin olive oil, provides high levels of omega-3 fatty acids (EPA and DHA) that suppress the expression of inflammatory enzymes at a systemic level, such as COX-2.

In clinical settings, standardized curcumin (the anti-inflammatory polyphenol in turmeric) and Boswellia serrata (frankincense extract) are clinically effective in reducing joint pain scores in randomized trials, without affecting central nervous system protein glycosylation.

Besides, topical NSAID gels, such as over-the-counter diclofenac gel, can be applied directly to the joint surface and have minimal systemic absorption, which means no gastrointestinal upset and no central nervous system exposure.

If you or a family member is experiencing minor memory lapses or has already been diagnosed with an early-onset cognitive disorder, collect all vitamins, herbal extracts, and over-the-counter supplements and bring them to your next primary care appointment. Request that your doctor or pharmacist review all medications for potential neurotoxicity, metabolic interactions, and blood-thinning risks.

Bottom line

The University of Florida researchers have found that glucosamine, a widely used OTC joint supplement, is linked to a 25% risk of transitioning from mild cognitive impairment to dementia, and a 25% risk of death within 5 years among those who have been diagnosed with Alzheimer’s disease. An overactive biological sugar-tagging system that attaches too many glycans to proteins in the brain can exacerbate damage in metabolically weak brains but not in healthy brains when boosted by glucosamine. Anyone with early memory loss or a personal history of memory loss should steer clear of glucosamine and seek well-established strategies to protect brain health, including low-impact aquatic exercise, topical anti-inflammatory gels, and anti-inflammatory nutrition.

Frequently Asked Questions

Which vitamin deficiency is most likely to cause dementia?

A severe deficiency in Vitamin B12 (cobalamin) is the most common nutritional deficiency that causes reversible dementia-like symptoms, memory loss, confusion, and peripheral nerve damage.

At what age does dementia typically start?

Dementia symptoms most commonly begin after age 65, with the prevalence doubling roughly every five years thereafter. However, rare early-onset forms of dementia can start between an individual’s late 30s and early 50s.

Citations

Cassella C. Popular Joint Supplement Linked to 25% Higher Dementia Risk in People With Early Memory Loss. ScienceAlert. Published September 29, 2026. https://www.sciencealert.com/popular-joint-supplement-linked-to-25-higher-dementia-risk

Hawkinson TR, Liu Z, Ribas RA, et al. Hyperglycosylation is a metabolic driver of Alzheimer’s disease. Nature Metabolism. Published online June 9, 2026. doi:10.1038/s42255-026-01538-4

Jaffee M. Study links joint pain supplement to accelerating dementia – UF Health. Ufhealth.org. Published 2026. https://ufhealth.org/news/2026/study-links-joint-pain-supplement-to-accelerating-dementia-2

Taylor T. Brain’s sugar processing may fuel Alzheimer’s pathology, study finds – UF Health. Ufhealth.org. Published 2026. https://ufhealth.org/news/2026/brains-sugar-processing-may-fuel-alzheimers-pathology-study-finds

Bailey RL. Current regulatory guidelines and resources to support research of dietary supplements in the United States. Critical Reviews in Food Science and Nutrition. 2020;60(2):298-309. doi:10.1080/10408398.2018.1524364

Mayo Clinic. Glucosamine. Mayo Clinic. Published 2017. https://www.mayoclinic.org/drugs-supplements-glucosamine/art-20362874

Alzheimer’s Association. 10 early signs and symptoms of alzheimer’s. Alzheimer’s Disease and Dementia. Published 2025. https://www.alz.org/alzheimers-dementia/10_signs

Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2021;73(7):924-939. doi:10.1002/acr.24596

The post The Link Between Glucosamine Joint Supplements And Dementia Risk, Explained appeared first on Blavity.